99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer

NCT06419348 · tracked via the Priya Life Science China tracker

Sponsor

First Affiliated Hospital of Chongqing Medical University

Phase

Phase EARLY_PHASE1

Started

2024-05-20

Last updated

2025-06-04

Condition(s) studied

Prostate Cancer StagePSMASPECT

Investigational drug(s) / intervention(s)

99mTc-QULIC-5-P1

99mTc-QULIC-5-P1: Each subject receives a single intravenous injection of 99mTc-QULIC-5-P1.

Study summary

99mTc-QULIC-5-P1 is a new radiotracer targeting PSMA, which is promising as an excellent imaging agent applicable to PSMA positive prostate cancer. This study will investigate the safety, biodistribution and potential usefulness of 99mTc-QULIC-5-P1 SPECT imaging for the diagnosis of lesions in PSMA positive prostate cancer.

Eligibility

Sex

MALE

Min age

18 Years

Max age

—

Healthy volunteers

Accepted

Inclusion Criteria: 1. At least 18 years of age. 2. Signed informed consent. 3. Patients with suspected or newly diagnosed or previously prostate cancer, with PSMA positive expression (supporting evidence may include MRI, CT, and pathology report, etc). Exclusion Criteria: 1. Patients with PSMA negative expression. 2. Patients with pregnancy. 3. The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent. 4. Known or expected hypersensitivity to 99mTc-QULIC-5-P1 or any of its components. 5. Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study.

Primary outcome measure(s)

Diagnostic efficacy — 15 days
The sensitivity, specificity, and accuracy of 99mTc-QULIC-5-P1 SPECT

Trial sites (1)

Facility	City	Region	Status
The First Affiliated Hospital of Chongqing Medical University	Chongqing	Chongqing Municipality	Recruiting

More First Affiliated Hospital of Chongqing Medical University trials in China

Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment Recruiting

Sertraline Combined With Multi-Strain Probiotics for Adolescent Depression Recruiting

Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study Starting soon

Metabolomics Predictors for Metabolic Disease Remission After Metabolic Syndrome Surgery. Active, not recruiting

An Integrated Multi-omics Study on the Molecular Mechanisms of Ureteral Stricture Starting soon

Other trials for the same condition

68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive Disease Recruiting

Artificial Intelligence Models for Precision Prediction and Treatment of Prostate Cancer Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06419348 on ClinicalTrials.gov ↗ ← All trials in China